Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

Blood

Volumn 116, Issue 15, 2010, Pages 2858-2859

  Yokoyama, Hisayuki ^a   Lundqvist, Andreas ^b   Su, Su ^b   Childs, Richard ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG EFFECT; DRUG SAFETY; HLA MATCHING; LETTER; LEUKEMIA RELAPSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROPHYLAXIS; T CELL DEPLETION; T LYMPHOCYTE; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, RENAL CELL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY NEOPLASMS; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77957950672     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-291104     Document Type: Letter

References (1)

1. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567-6571.